AUSTRALIAN SPORTS ANTI-DOPING AUTHORITY 2010:11 ANNUAL REPORT
© Commonwealth of Australia
ISSN 1833-8976
Table of Contents
Letter of transmittal 3
About this report 4
Message from the CEO 10
Organisational overview 15
About ASADA 16
Legislative basis 16
Role and functions 16
Goals 17
Australia’s anti‑doping structure 17
Minister for Sport 18
Australian Sports Anti‑Doping Authority 18
Outcome and program structure 19
Highlights of 2010–11 20
Report on performance 23
Program 1.1 – Deterrence, detection and enforcement 24
Deliverables 24
Key performance indicators 26
Building awareness 28
Communication campaigns 28
Digital marketing 30
Media 32
Printed resources 34
Education 35
Partnerships 38
Assisting sporting organisations 41
Sports forums 41
Liaison with national sporting bodies 42
International engagement 43
Detection 46
National testing and sport operations program 46
Pure Performance programs 48
User-pays tests 48
Long-term storage facility 49
Accreditation of Doping Control Officers and Chaperones 50
Investigations and intelligence 51
Athlete whereabouts 52
Enforcement 54
Athlete counselling service 56
Management and accountability 59
Corporate governance 60
Corporate and operational planning 60
Organisational structure and Senior Executive arrangements 61
Chief Executive Officer 62
Anti‑Doping Programs and Legal Services 62
Operations 62
Governance committees 62
Risk management 63
Ethical standards 65
Internal audits 66
Recordkeeping 66
Quality management 67
External scrutiny 68
Significant developments 68
Decisions and reports 68
Management of human resources 69
Workforce planning 70
Attraction and retention 70
Employment agreements 71
Section 24(1) determinations 71
Non-salary benefits 71
Performance Management System 71
Australia Day medallions 72
Peer recognition 72
Staff consultation 73
Learning and development 73
Workplace diversity 74
Commonwealth Disability Strategy 74
Occupational health and safety 75
Financial information 77
Summary of financial performance 2010–11 78
Grant programs 78
Asset management 78
Purchasing 79
Engagement of consultants and contractors 79
Consultants 79
Competitive tendering and contracting 81
Auditor-General access 81
Exempt contracts 81
Financial statements 83
ASADA Advisory Group 137
Overview 138
Advisory Group members 138
Resources 139
Anti‑Doping Rule Violation Panel 141
Overview 142
ADRVP members 142
Resources 144
Australian Sports Drug Medical Advisory Committee 147
Therapeutic approvals for prohibited substances 148
ASDMAC members 149
Achievements 151
Resources 151
Freedom of information procedures and ASDMAC contact details 151
Appendixes 155
Appendix A: Doping control statistics 2000–01 to 2010–11 156
Appendix B: Publicly announced Anti‑Doping rule violations 2010–11 157
Appendix C: International anti‑doping and doping control 161
Appendix D: Powers of the Minister to give directions to ASADA and the CEO 162
Appendix E: ASADA and CEO functions, powers and delegations 163
CEO’s functions 163
CEO’s powers 164
Appendix F: Staffing statistics at 30 June 2011 165
Appendix G: Occupational health and safety 168
Appendix H: Advertising and market research 169
Appendix I: Ecologically sustainable development and environmental performance 170
Principles of the legislation 170
Measures taken to minimise environmental impact 170
Appendix J: Freedom of information 171
Organisation and functions of ASADA 171
Decision-making powers 171
Authorised freedom of information decision makers 171
Arrangements for consulting external bodies or people 171
Categories of documents 171
Facilities for the public to obtain physical access to ASADA documents 172
Departmental manuals 172
Freedom of information procedures and ASADA contact details 172
Appendix K: Australian Sports Drug Medical Advisory Committee – functions 174
Appendix L: Australian Sports Drug Medical Advisory Committee – Therapeutic Use Exemptions
(TUEs) granted 175
Appendix M: Anti‑Doping Rule Violation Panel – functions 178
Appendix N: Expenses and resources for Outcome 1 179
Appendix O: ASADA Resource Statement 2010–11 180
Abbreviations and glossary 183
List of abbreviations 184
Glossary 186
Indexes 191
Compliance index 192
Alphabetical index 196
List of Figures
Figure 1: Australia’s anti‑doping framework 18
Figure 2: Outcome and program structure 2010–11 19
Figure 3: Number of athletes and support personnel recording anti‑doping rule violations 56
Figure 4: Organisational structure at 30 June 2011 62
List of Tables
Table 1: Program 1.1 qualitative deliverables 24
Table 2: Program 1.1 quantitative deliverables 25
Table 3: Program 1.1 qualitative key performance indicators 26
Table 4: Program 1.1 quantitative key performance indicators 27
Table 5: Online substance searches and visitors 31
Table 6: Education activities undertaken during 2010–11 37
Table 7: Satisfaction with ASADA education 39
Table 8: Anti‑doping tests conducted by ASADA in 2010–11 48
Table 9: Doping control facts and figures 2010–11 51
Table 10: Substances involved in anti‑doping matters 2010–11 54
Table 11: Breakdown of anti‑doping rule violations 2010–11 55
Table 12: Expenditure on new and existing consultancy contracts 2010–11 79
Table 13: Consultancy services let during 2010–11 of $10,000 or more 80
Table 14: ADRVP attendance 2010–11 143
Table 15: ADRVP expenses 2010–11 144
Table 16: ASDMAC members 149
Table 17: ASDMAC expenses 2010–11 151
Table 18: ASDMAC freedom of information statistics 152
Table 19: Doping control statistics 156
Table 20: Publicly announced anti‑doping rule violations 157
Table 21: Entries on Register of Findings 2009–10 where the outcomes were to be advised 160
Table 22: Government-to-government arrangements 161
Table 23: Full-time and part-time staff at 30 June 2011 165
Table 24: Staff by classification groups and location at 30 June 2011 165
Table 25: SES staff at 30 June 2011 165
Table 26: Staff in equal employment opportunity groups at 30 June 2011 166
Table 27: Salary ranges of employees 166
Table 28: Number of staff in the collective agreement or Section 24(1) determinations 167
Table 29: Advertising and market research 169
Table 30: ASADA freedom of information statistics 173
Table 31: Therapeutic use exemptions granted 175
Table 32: Substances and methods approved for therapeutic use 2010–11 177
Table 33: Expenses and resources for Outcome 1 179
Table 34: ASADA Resource Statement 180
